On July 21, Qingsong Health rose 9.56% in regular trading, trading at 6.45 HKD/share, with turnover of 33.16 million HKD. The stock had been under sustained selling pressure after the company issued a profit warning projecting H1 losses of RMB 40-70 million, compared to a profit of approximately RMB 86 million in the prior-year period.
On the news front, the company recently appeared at the World Artificial Intelligence Conference, showcasing its evidence-based medical AI agent product Zheng Yuan Fang and derivative products Zheng Jing and Zheng Yin, demonstrating landing progress across medical scenarios. Additionally, the company was awarded the Securities Star Social Value Co-creation Award, gaining industry recognition for its ESG practices. The loss was attributed primarily to significantly increased R&D spending on AI model training and related data procurement for medical knowledge bases.
Following consecutive sessions of decline that brought market capitalization to approximately HKD 1.3 billion, these positive signals appear to have triggered renewed market attention toward the company's long-term AI healthcare strategy.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments